An Oxford spinout raises $44M as it looks to resurrect an old Roche antibody in pursuit of a rare disease
Three months ago, a small and little-known Oxford University spinout called Celleron announced they would try to resurrect an antibody Roche retired back in 2018. Now that spinout is spinning out its own new company and raising cash from a high-profile investor to push that antibody through the clinic.
Backed with €37 million in Series A cash, SynOx Therapeutics will look to develop the antibody, known as emactuzumab, for tenosynovial giant cell tumours (TGCT), a rare disease where series of benign tumors begin to grow around the joints and tendons. HealthCap and Medicxi led the round and were joined by Forbion and Gimv.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
